Clinical Trial Update: Ruxolitinib for Acute Respiratory Disorder Syndrome Due to COVID-19 [Phase 2, Phase 3]

View source ↗

Summary

A phase 2/3 trial of ruxolitinib for acute respiratory distress syndrome due to COVID-19 was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syndrome Coronavirus 2 Infection

Drugs mentioned

• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Vanderson Geraldo Rocha | Conditions: Severe Acute Respiratory Syndrome Coronavirus 2, SARS-CoV2 | Phase 2, Phase 3 | Status: TERMINATED